Affluent Medical SA (FR:AFME) has released an update.
Affluent Medical SA, a French medtech firm specializing in treatments for structural heart diseases and urinary incontinence, has disclosed its total number of voting rights and shares. The company, which is in the process of human clinical trials for its innovative implants, plans to initiate product commercialization by 2026 subject to successful funding and study outcomes. Interested parties can find more details on the company’s progress and strategies on their website.
For further insights into FR:AFME stock, check out TipRanks’ Stock Analysis page.
